FOLFIRINOX方案在胰腺癌治疗中的应用

doi:10.3760/cma.j.issn.1673-422X.2017.11.018

摘要/Abstract

摘要： 临床研究已证实FOLFIRINOX方案（奥沙利铂+伊立替康+氟尿嘧啶+亚叶酸钙）是体能状态良好的胰腺癌患者的有效化疗方案。目前关于FOLFIRINOX方案的临床研究主要包括FOLFIRINOX方案新辅助治疗不可手术切除或临界可切除胰腺癌以及一线治疗局部进展期胰腺癌和转移性胰腺癌，提高了患者手术切除机会以及生存时间。此外，FOLFIRINOX方案的不良反应、安全性以及有效人群的选择也是研究者关注的热点。

关键词: 胰腺肿瘤, 药物疗法, FOLFIRINOX方案

Abstract: Clinical studies have confirmed the FOLFIRINOX regimen (oxaliplatin+irinotecan+fluorouracil+leucovorin) is an effective regimen for advanced pancreatic cancer patients with good performance status. Current clinical studies on FOLFIRINOX regimen mainly include neoadjuvant therapy for unresectable and borderline resectable pancreatic cancer and firstline therapy for locally advanced pancreatic cancer and metastatic pancreatic cancer, which improved patient′s surgical resection opportunities and survival. In addition, the toxicity, safety of FOLFIRINOX regimen and effective population selection for FOLFIRINOX regimen are also the problems concerned by researchers.

Key words: Pancreatic neoplasms, Drug therapy, FOLFIRINOX regimen

于兰，张小涛，李进英，王玉. FOLFIRINOX方案在胰腺癌治疗中的应用[J]. 国际肿瘤学杂志, 2017, 44(11): 874-878.

于兰，张小涛，李进英，王玉. Clinical application of FOLFIRINOX regimen for pancreatic cancer[J]. Journal of International Oncology, 2017, 44(11): 874-878.

参考文献

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387. ［2］ Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States［J］. Cancer Res, 2014, 74(11): 2913-2921. DOI: 10.1158/0008-5472.CAN-14-0155. ［3］ Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges［J］. Nat Rev Clin Oncol, 2010, 7(3): 163-172. DOI: 10.1038/nrclinonc.2009.236. ［4］ Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer［J］. N Engl J Med, 2011, 364(19): 1817-1825. DOI: 10.1056/NEJMoa1011923. ［5］ Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages［J］. PLoS Med, 2010, 7(4): e1000267. DOI: 10.1371/journal.pmed.1000267. ［6］ Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma—a systematic review and metaanalysis［J］. Cancer Treat Rev, 2017, 55: 96-106. DOI: 10.1016/j.ctrv.2017.03.003. ［7］ Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabinebased chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101［J］. JAMA Surg, 2016, 151(8): e161137. DOI: 10.1001/jamasurg.2016.1137. ［8］ Khushman M, Dempsey N, Maldonado JC, et al. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma［J］. Pancreatology, 2015, 15(6): 667-673. DOI: 10.1016/j.pan.2015.08.010. ［9］ Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients［J］. Ann Surg, 2016, 264(3): 457-463. DOI: 10.1097/SLA.0000000000001850. ［10］ Pietrasz D, Marthey L, Wagner M, et al. Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEOFRENCH, prospective, multicentric cohort［J］. Ann Surg Oncol, 2015, 22 Suppl 3: S11961205. DOI: 10.1245/s10434-015-4783-x. ［11］ Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts general hospital cancer center experience［J］. Oncologist, 2013, 18(5): 543-548. DOI: 10.1634/theoncologist.2012-0435. ［12］ Marthey L, SaCunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort［J］. Ann Surg Oncol, 2015, 22(1): 295-301. DOI: 10.1245/s10434-014-3898-9. ［13］ Mellon EA, Hoffe SE, Springett GM, et al. Longterm outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma［J］. Acta Oncol, 2015, 54(7): 979-985. DOI: 10.3109/0284186X.2015.1004367. ［14］ Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patientlevel metaanalysis［J］. Lancet Oncol, 2016, 17(6): 801810. DOI: 10.1016/S1470-2045(16)00172-8. ［15］ Marthey L, SaCunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort［J］. Ann Surg Oncol, 2015, 22(1): 295301. DOI: 10.1245/s1043401438989. ［16］白雪莉, 苏日嘎, 马涛, 等. 改良FOLFIRINOX方案治疗进展期胰腺癌单中心经验［J］. 中华外科杂志, 2016, 54(4): 270-275. DOI: 10.3760/cma.j.issn.0529-5815.2016.04.006. ［17］ Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer［J］. J Gastrointest Oncol, 2014, 5(4): 280-295. DOI: 10.3978/j.issn.20786891.2014.030. ［18］ Cinar P, Ko AH. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017［J］. Chin Clin Oncol, 2017, 6(3): 29. DOI: 10.21037/cco.2017.06.13. ［19］ Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group［J］. J Clin Oncol, 2007, 25(15): 1960-1966. DOI: 10.1200/JCO.2006.07.9525. ［20］ Zahir MN, Jabbar AA. Metastatic pancreatic carcinoma and experience with FOLFIRINOXa cross sectional analysis from a developing country［J］. Asian Pac J Cancer Prev, 2015, 16(14): 60016006. ［21］ Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?［J］ Lancet Oncol, 2011, 12(1): 8-9. DOI: 10.1016/S1470-2045(10)70237-0. ［22］ Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK singlecentre experience［J］. Oncology, 2015, 89(5): 281-287. DOI: 10.1159/000439171. ［23］ Orlandi A, Calegari MA, Martini M, et al. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1positive: everything was not too bad back when everything seemed worse［J］. Clin Transl Oncol, 2016, 18(10): 988-995. DOI: 10.1007/s120940151471z. ［24］ Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma［J］. J Natl Cancer Inst, 2015, 107(8). pii: ajv132. DOI: 10.1093/jnci/djv132.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[4]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[5]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[6]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[7]	魁国菊, 黄江宾, 张文华, 杨立民. 区域淋巴结大小对胰头腺癌术后复发的影响[J]. 国际肿瘤学杂志, 2023, 50(10): 608-613.
[8]	陈怡, 韩靓, 蔡雳. 头颈部肿瘤患者化疗性口腔黏膜炎发生的多因素分析[J]. 国际肿瘤学杂志, 2022, 49(9): 521-525.
[9]	褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰. 化疗剂量强度对晚期结肠癌患者近期疗效的影响：基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415.
[10]	韩丛丛, 付帅, 谢超, 张建军, 张秋景, 祝情情, 刘杰. 吉非替尼、培美曲塞和贝伐珠单抗一线治疗EGFR突变晚期肺腺癌的有效性和安全性[J]. 国际肿瘤学杂志, 2022, 49(6): 376-379.
[11]	唐琳, 相明月, 张建波, 王丽丽, 巩合义, 韩大力. 卡瑞利珠单抗联合阿帕替尼及化疗二线或以上治疗HER-2阴性晚期胃癌的临床疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(5): 276-281.
[12]	张绍鹏, 孔远, 潘国强, 朱丽, 王大广. 全身化疗联合腹腔热灌注治疗胃癌1例[J]. 国际肿瘤学杂志, 2022, 49(5): 316-318.
[13]	高世乐, 芦东徽, 刘美琴, 徐兴军, 马欢, 张羽. 阿帕替尼联合化疗在晚期非小细胞肺癌患者中的临床疗效和最佳剂量探讨[J]. 国际肿瘤学杂志, 2022, 49(3): 140-145.
[14]	劳峥, 涂文勇, 徐璇丽, 张霖, 邵滋旸, 石慧烽. 尼妥珠单抗联合根治性放疗治疗局部晚期不可手术的口腔颌面部鳞状细胞癌[J]. 国际肿瘤学杂志, 2022, 49(11): 665-670.
[15]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏. 晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.